IsoPSA Performance Characteristics Are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results from the IsoPSA Validation Study

    February 2023 in “ Urology ”
    Jason Scovell, Mark Stovsky, Alan W. Partin … Eric A. Klein
    Studysummary This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on goldjournal.net →
    Discuss this study in the Community →